Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery - a retrospective analysis

Journal of Cardiothoracic Surgery

Volumn 11, Issue 1, 2016, Pages

  Grieshaber, Philippe ^a   Lipp, Stella ^a   Arnold, Andreas ^a   Görlach, Gerold ^a   Wollbrück, Matthias ^a   Roth, Peter ^a   Niemann, Bernd ^a   Wilhelm, Jochen ^b   Böning, Andreas ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Cardiac surgery; High risk patients; Levosimendan; Low cardiac output syndrome

Indexed keywords

CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADVERSE EFFECTS; AGED; ATRIAL FIBRILLATION; CARDIOPULMONARY BYPASS; CHEMICALLY INDUCED; COMPLICATION; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECTS; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; KIDNEY; MALE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; FEMALE; HUMANS; HYDRAZONES; KIDNEY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PYRIDAZINES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84999806622     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/s13019-016-0556-2     Document Type: Article

References (27)

1. Lilleberg J, Nieminen MS, Akkila J, Heikkilä L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660-8.
2. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake. Circulation. 2005;111:1504-9.
3. Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-32.
4. Follath F, Cleland JGF, Just H, Papp JGY, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet Lond Engl. 2002;360:196-202.
5. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. Jacc Heart Fail. 2013;1:103-11.
6. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999;34:219-28.
7. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, Pietropaoli P, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102:198-204.
8. Bragadottir G, Redfors B, Ricksten S-E. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41:2328-35.
9. Niu Z-Z, Wu S-M, Sun W-Y, Hou W-M, Chi Y-F. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis. J. Cardiovasc. Pharmacol. 2014;63(2):107-12.
10. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol. 2004;93:1309-12.
11. De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg. 2007;104:766-73.
12. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17:125-30.
13. Maharaj R, Metaxa V. Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Crit Care. 2011;15:R140.
14. Landoni G, Mizzi A, Biondi-Zoccai G, Bruno G, Bignami E, Corno L, et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2010;24:51-7.
15. Lehmann A, Radke J, Sack F-U. Levosimendan - an inoprotective drug or much ado about nothing?*: Crit. Care Med. 2011;39:2365-6.
16. Carl M, Alms A, Braun J, Dongas A, Erb J, Goetz A, et al. S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system. Gms Ger. Med. Sci. [Internet]. 2010 [cited 2016 Jun 30];8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890209/
17. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care Lond Engl. 2007;11:R31.
18. Koster G, Wetterslev J, Gluud C, Zijlstra JG, Scheeren TWL, van der Horst ICC, et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;41:203-21.
19. Shi WY, Li S, Collins N, Cottee DB, Bastian BC, James AN, et al. Peri-operative levosimendan in patients undergoing cardiac surgery: an overview of the evidence. Heart Lung Circ. 2015;24:667-72.
20. Lahtinen P, Pitkanen O, Polonen P, Turpeinen A, Kiviniemi VL, Uusaro A. Levosimendan reduces heart failure after cardiac surgery: A prospective, randomized, placebo-controlled trial*. Crit Care Med. 2011;39:2263-70.
21. Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health. 2004;58:635-41.
22. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312:1215-8.
23. Sanson-Fisher RW, Bonevski B, Green LW, D'Este C. Limitations of the Randomized Controlled Trial in Evaluating Population-Based Health Interventions. Am J Prev Med. 2007;33:155-61.
24. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial apply?". Lancet. 2005;365:82-93.
25. Toller W, Heringlake M, Guarracino F, Algotsson L, Alvarez J, Argyriadou H, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol. 2015;184:323-36.
26. Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013;27(6):1224-32.
27. Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report 2015 [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015 [cited 2016 Nov 6]. Available from: http://link.springer.com/ 10.1007/978-3-662-47186-9